Overview

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2015-05-08
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S